Cardiac Arrest, Therapeutic Hypothermia
Conditions
Keywords
Cardiac arrest, Therapeutic hypothermia, Sevoflurane, Sedation, Patient resuscitated from cardiac arrest, Requiring sedation, Adult patients, Patient covered by french health care system
Brief summary
Studying the feasibility of an initial sedation with inhalated sevoflurane during therapeutic hypothermia of cardiac arrests resuscitated patients.
Detailed description
Prospective clinical study in ICU with ventilated patients sedated with sevoflurane using the Mirus® and Anaconda® , establishing the feasibility of an initial sedation of patients resuscitated from cardiac arrest and treated with therapeutic hypothermia.
Interventions
DRUGsevoflurane
Sponsors
University Hospital, Estaing
Hopital Gabriel Montpied
University Hospital, Clermont-Ferrand
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* -Adult patients ventilated requiring therapeutic hypothermia in ICU * Stable respiratory and hemodynamic conditions * Epinephrine and norepinephrine infusion rate \< 1,5 g/kg/min * Consent of patients or family * Arterial line * Patients resuscitated after cardiac arrest * No Flow \< 10 min * Low Flow \< 20 min * Neutropenia \< 1 G/L * Post traumatic cardiac arrest * Contraindication of halogenated anesthesics * Extra corporeal life support or intra aortic balloon pump
Exclusion criteria
* -Pregnant woman * Hemodynamic instability * Brain death defined by the disappearance of brain stem reflexes
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Determination of the feasibility of a sedation with inhalated sevoflurane in cardiac arrest resuscitated patients | at day 1 | The feasibility is evaluated by the number of side effects due to treatment until discharge from hospital. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Determination of neurological prognostic of patients at ICU and hospital discharge | at day 1 | — |
| Determination of systemic complications and organ failures during hospitalisation | at day 1 | — |
| Evaluation of systemic inflammation and evolution with cytokines | at day 1 | — |
| Evaluation of markers specific of brain ischemia (S100 protein and neuron-specific enolase) | at day 1 | at 3 times: before starting sevoflurane sedation, 24 hours, 48 hours and 72 hours after starting sevoflurane sedation. |
Countries
France
Outcome results
None listed